NAGOYA UNIVERSITY
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1871-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.nagoya-u.ac.jp/en
Clinical Trials
24
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma BladderUrothelial Carcinoma RecurrentUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma Urethra
- Interventions
- Drug: Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 43
- Registration Number
- NCT06983210
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya-shi, Aichi, Japan
Deep Learning-based Artificial Intelligence for the Diagnosis of Small Bowel Obstruction
- Conditions
- Bowel ObstructionArtificial Intelligence
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 17
- Registration Number
- NCT06481358
- Locations
- 🇯🇵
Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
Investigator-initiated Clinical Trial of MIKE-1
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 55
- Registration Number
- NCT05064618
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya, Aich, Japan
🇯🇵The University of Tokyo Hospital, Tokyo, Japan
The Clinical Trial of ADR-001 for IgA Nephropathy
- Conditions
- Glomerulonephritis , IGA
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 9
- Registration Number
- NCT04342325
- Locations
- 🇯🇵
Kasugai Municipal Hospital, Kasugai, Aichi, Japan
🇯🇵Nagoya University Hospital, Nagoya, Aichi, Japan
The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy
- Conditions
- Hypoxia-Ischemia, Brain
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 9
- Registration Number
- NCT04261335
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya, Aich, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Elix and LINC Launch World's First Commercial AI Drug Discovery Platform Using Federated Learning from 16 Pharmaceutical Companies
Elix and LINC have commercialized the world's first AI drug discovery platform incorporating federated learning models trained on data from 16 pharmaceutical companies, addressing the critical data scarcity challenge in AI drug discovery.
Fujitsu and THERS Successfully Deploy AI to Accelerate Clinical Trial Recruitment and Combat Drug Loss in Japan
Fujitsu and Tokai National Higher Education and Research System (THERS) have completed successful field trials using generative AI to structure clinical data, achieving approximately 90% accuracy with 1,800 breast surgery patient records.